SCHEMBL6665062

SCHEMBL6665062

CCOC(OCC)c1ccc(Nc2ncnc3cc(OC)c(OC)cc23)cc1Br

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 13/20 0.70
ABCG2 Q9UNQ0 3/20 0.66
JAK3 P52333 3/20 0.66
ABCB1 P08183 1/20 0.66
KDR P35968 7/20 0.64
CLK1 P49759 1/20 0.62
LCK P06239 3/20 0.61
MKNK1 Q9BUB5 2/20 0.60
SRC P12931 2/20 0.60
ERBB2 P04626 3/20 0.59
FBP1 P09467 2/20 0.59
GAK O14976 2/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPK13 O15264 1/20 0.59
ABL1 P00519 1/20 0.59
CYP1A2 P05177 1/20 0.59
CDK1 P06493 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
MAPT P10636 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5570070 0.83 EGFR (0.85) EGFRABCG2JAK3ABCB1KDR
SCHEMBL5865262 0.81 EGFR (0.81) EGFRABCG2JAK3ABCB1KDR
SCHEMBL29711485 0.80 JAK3 (1.00) EGFRABCG2JAK3ABCB1KDR
SCHEMBL20812874 0.80 EGFR (0.80) EGFRABCG2JAK3ABCB1KDR
SCHEMBL29651 0.80 JAK3 (1.00) EGFRABCG2JAK3ABCB1KDR
SCHEMBL29372372 0.80 JAK3 (1.00) EGFRABCG2JAK3ABCB1KDR
SCHEMBL14095971 0.80 EGFR (0.80) EGFRABCG2JAK3ABCB1KDR
SCHEMBL5467825 0.79 EGFR (1.00) EGFRABCG2JAK3ABCB1KDR
SCHEMBL6664095 0.79 EGFR (0.78) EGFRABCG2JAK3ABCB1KDR
SCHEMBL12963484 0.78 FBP1 (0.91) EGFRABCG2KDRMKNK1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004013091-A2 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-02-12 WO claimed
WO-2004013091-A2 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2004-02-12 WO disclosed